- Home
- UTHR vs TOL Comparison
UTHR vs TOL Comparison
Compare UTHR & TOL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UTHR
- TOL
- Stock Information
- Founded
- UTHR 1996
- TOL 1967
- Country
- UTHR United States
- TOL United States
- Employees
- UTHR N/A
- TOL N/A
- Industry
- UTHR Biotechnology: Pharmaceutical Preparations
- TOL Homebuilding
- Sector
- UTHR Health Care
- TOL Consumer Discretionary
- Exchange
- UTHR Nasdaq
- TOL Nasdaq
- Market Cap
- UTHR 20.7B
- TOL 13.8B
- IPO Year
- UTHR 1999
- TOL N/A
- Fundamental
- Price
- UTHR $470.30
- TOL $130.98
- Analyst Decision
- UTHR Buy
- TOL Buy
- Analyst Count
- UTHR 12
- TOL 15
- Target Price
- UTHR $495.08
- TOL $150.87
- AVG Volume (30 Days)
- UTHR 573.8K
- TOL 956.2K
- Earning Date
- UTHR 10-29-2025
- TOL 12-08-2025
- Dividend Yield
- UTHR N/A
- TOL 0.76%
- EPS Growth
- UTHR 16.08
- TOL N/A
- EPS
- UTHR 26.38
- TOL 13.61
- Revenue
- UTHR $3,128,400,000.00
- TOL $10,876,787,000.00
- Revenue This Year
- UTHR $13.68
- TOL $0.45
- Revenue Next Year
- UTHR $5.63
- TOL N/A
- P/E Ratio
- UTHR $17.53
- TOL $9.69
- Revenue Growth
- UTHR 13.50
- TOL 3.26
- 52 Week Low
- UTHR $266.98
- TOL $86.67
- 52 Week High
- UTHR $479.50
- TOL $169.52
- Technical
- Relative Strength Index (RSI)
- UTHR 67.63
- TOL 40.07
- Support Level
- UTHR $444.04
- TOL $131.00
- Resistance Level
- UTHR $464.27
- TOL $137.25
- Average True Range (ATR)
- UTHR 15.76
- TOL 3.70
- MACD
- UTHR 1.70
- TOL -0.32
- Stochastic Oscillator
- UTHR 85.27
- TOL 6.11
About UTHR United Therapeutics Corporation
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.
About TOL Toll Brothers Inc.
Toll Brothers is the leading luxury homebuilder in the United States with an average sale price well above public competitors'. The company operates in over 60 markets across 24 states and caters to move-up, active-adult, and second-homebuyers. Traditional homebuilding operations represent most of company's revenue. Toll Brothers also builds luxury for-sale and for-rent properties in urban centers across the US. It has its headquarters in Horsham, Pennsylvania.